Oppenheimer raised the firm’s price target on Ascendis Pharma (ASND) to $215 from $180 and keeps an Outperform rating on the shares. The firm notes Q1 Yorvipath sales of EUR 44.7M blew past EUR 29.5M mean broker estimate in this product’s first full U.S. commercial quarter. Although U.S. sales of EUR 26M got a boost from conversion of the about 200 expanded access patients to paid drug, the print increases Oppenheimer’s confidence in Ascendis’ execution and its conviction that Yorvipath’s sales trajectory will surpass expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $210 from $205 at RBC Capital
- Ascendis Pharma price target raised to $212 from $181 at Wedbush
- Ascendis Pharma price target raised to $245 from $200 at JPMorgan
- Ascendis Pharma’s Yorvipath Drives Strong US Market Performance and Promising Long-term Outlook, Justifying Buy Rating
- Ascendis Pharma Reports Strong Q1 2025 Performance